ABEONA THERAPEUTICS INC. Long-Term Debt, Maturity, Remainder of Fiscal Year
ABEONA THERAPEUTICS INC. (ABEO) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $6.67 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-13
- 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $6.67M.
- 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $10.00M.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $5.93M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $6.67M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $10.00M 10-Q · filed 2026-05-13 |
| 2025-03-31 | $5.93M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |